Accelerating Discovery

Through a Better Platform

Our proprietary software platform supports the rapid discovery, iteration, and evaluation of new behavioral therapeutics targeting diseases caused or complicated by poor quality nutrition.

2024
Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes
A Peer Reviewed Study. Advances in Therapy, 2023
2023
A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
A Peer Reviewed Study. Gastro Hep Advances, 2023.
2023
A Novel Prescription Digital Therapeutic for the Treatment of Non-alcohol Related Fatty Liver Disease
A feasibility study poster presented at the EASL Congress 2023.
2022
Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes
A Peer Reviewed Study. Diabetes Care, 2022.
2022
Randomized, Controlled Trial of a Digital Therapeutic App Providing Cognitive Behavioral Therapy for the Treatment of Type 2 Diabetes: Primary Results of the BT-001 Pivotal Trial
A Poster Presentation. Cardiometabolic Health Congress, 2022.
2022
BT-001 Pivotal Clinical Trial Design
A Peer Reviewed Rationale and Design Manuscript. Clinical Cardiology, 2022.
2020
Impact of Nutritional CBT Delivered by a Mobile Application in Adults with Type 2 Diabetes
Pilot Study Findings.
2019
Estimating the Impact of Novel Digital Therapeutics in Type 2 Diabetes and Hypertension: Health Economic Analysis
A Peer Reviewed Study. Journal of Medical Internet Research, 2019.
2019
Estimating the Economic Impact of Novel Digital Therapeutics in Type 2 Diabetes and Hypertension
Poster Presentation at IPSOR 2019 Conference
2020
Emergence of Digital Biomarkers to Predict and Modify Treatment Efficacy: Machine Learning Study
A Peer Reviewed Study. Journal of the Endocrine Society, 2020.
2020
SAT-LB120 A Software Application Delivering Behavioral Therapy Improved Glycemic Control in Adults With Type 2 Diabetes
Published Abstract. Journal of the Endocrine Society, 2020
2019
Achieving Rapid Blood Pressure Control With Digital Therapeutics: Retrospective Cohort and Machine Learning Study
A Peer Reviewed Study. Journal of Medical Internet Research, 2019.
2018
Change in Glycemic Control With Use of a Digital Therapeutic in Adults With Type 2 Diabetes: Cohort Study
A Peer Reviewed Study. Journal of Medical Internet Research, 2018.
2017
FareWell and the How of Lifestyle Medicine
A Peer Reviewed Publication. American Journal of Lifestyle Medicine, 2017

Top-Line Results from Pivotal Trial of BT-001, 2022

Positive primary and secondary endpoint data from pivotal clinical trial for type 2 diabetes digital therapeutics.

Learn More

Pilot Data Presented at Endocrine 2020

This study represents an important milestone on the path to regulatory approval, demonstrating that a software-only product configuration delivering behavioral therapy can produce meaningful outcomes in patients.

Have a question or want to learn more? Get in touch and let us know what's on your mind.

Get In Touch

Accelerating Discovery

Through a Better Platform

Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes

A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease

A Novel Prescription Digital Therapeutic for the Treatment of Non-alcohol Related Fatty Liver Disease

Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes

Randomized, Controlled Trial of a Digital Therapeutic App Providing Cognitive Behavioral Therapy for the Treatment of Type 2 Diabetes: Primary Results of the BT-001 Pivotal Trial

BT-001 Pivotal Clinical Trial Design

Impact of Nutritional CBT Delivered by a Mobile Application in Adults with Type 2 Diabetes

Estimating the Impact of Novel Digital Therapeutics in Type 2 Diabetes and Hypertension: Health Economic Analysis

Estimating the Economic Impact of Novel Digital Therapeutics in Type 2 Diabetes and Hypertension

Emergence of Digital Biomarkers to Predict and Modify Treatment Efficacy: Machine Learning Study

SAT-LB120 A Software Application Delivering Behavioral Therapy Improved Glycemic Control in Adults With Type 2 Diabetes

Achieving Rapid Blood Pressure Control With Digital Therapeutics: Retrospective Cohort and Machine Learning Study

Change in Glycemic Control With Use of a Digital Therapeutic in Adults With Type 2 Diabetes: Cohort Study

FareWell and the How of Lifestyle Medicine